As Ver­tex’s piv­otal pain read­out looms, non-opi­oid drug de­vel­op­ment faces a reck­on­ing

Last year
R&D
In Focus

De­cen­tral­ized tri­als start­up Cure­base scraps clin­i­cal op­er­a­tions busi­ness unit, nar­rows in on soft­ware plat­form

Last year
People
Startups

Gala­pa­gos seeks 's­trate­gic op­tion­s' for Jy­s­e­le­ca as JAK in­hibitor sales dis­ap­point again

Last year
Pharma

FDA hits Mesoblast with CRL, ask­ing for more adult da­ta in acute graft-ver­sus-host dis­ease

Last year
FDA+

Brent Saun­ders keeps rolling out the changes at Bausch + Lomb; In­cyte CSO to ex­it next month

Last year
Peer Review

Two deaths halt Re­gen­eron’s prostate can­cer bis­pe­cif­ic an­ti­body tri­al as it looks at tweak­ing com­bo plans

Last year
R&D

Gilead touts speed­i­er-than-ex­pect­ed pipeline ad­vances amid sol­id Q2 drug sales, ex­cept Covid-19 treat­ment Vek­lury

Last year
Pharma

Am­gen touts two can­cer study wins with DLL3, Lumakras amid sec­ond-quar­ter earn­ings up­date

Last year
R&D

Cor­rect­ed: Ken­tucky takes PBMs to court over 'outra­geous' in­sulin prices

Last year
Pharma
Law

Genen­tech up­dates spinal mus­cu­lar at­ro­phy ef­fort with new de­sign, so­cial me­dia and ‘Re­al Talk’

Last year
Pharma
Marketing

FDA ex­pands Mer­ck­'s Ebo­la vac­cine ap­proval to chil­dren one year and old­er

Last year
Pharma

FDA’s de­cen­tral­ized tri­al guid­ance: PhRMA, Mayo Clin­ic and oth­ers seek tweaks

Last year
Pharma
FDA+

Man­u­fac­tur­ing roundup: Mus­tang Bio clos­es sale with uBri­Gene; In­di­an syrup man­u­fac­tur­er halts pro­duc­tion af­ter ...

Last year
Manufacturing

J&J sets its sights on par­ents — and chil­dren’s vi­sion — in new back-to-school so­cial me­dia cam­paign

Last year
R&D

In­no­force names De­wan Zeng as the new CEO

Last year
People
China

Re­gen­eron plans for quick re­de­ci­sion on CRL for high­er dose of Eylea

Last year
Pharma
FDA+

Up­dat­ed: Seagen de­pri­or­i­tizes an­ti­body-drug can­di­date from $4.2B Mer­ck deal

Last year
Deals

George Church-en­dorsed start­up seeks 'al­ter­na­tives'; DOJ clos­es On­pat­tro mar­ket­ing in­ves­ti­ga­tion

Last year
News Briefing

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Last year
Deals
R&D

No­var­tis, Io­n­is will work to­geth­er again in the next-gen­er­a­tion car­dio space

Last year
Deals

Bausch + Lomb CEO Brent Saun­ders search­es for small­er deals while 'di­gest­ing' $1.75B Xi­idra move

Last year
Deals

Hous­ton biotech Ar­a­vive re­ports PhI­II ovar­i­an can­cer fail, shares nose­dive

Last year
R&D

Play­ground Glob­al, a16z back $26M seed for RNA edit­ing start­up aim­ing to ad­dress mul­ti­ple mu­ta­tions with sin­gle shot

Last year
Financing
Startups

Sarep­ta dos­es first pa­tient with Duchenne gene ther­a­py fol­low­ing ac­cel­er­at­ed ap­proval

Last year
R&D
Cell/Gene Tx
First page Previous page 301302303304305306307 Next page Last page
A service from the Financial Times